Soros Fund Management’s Astria Therapeutics ATXS Stock Holding History

Soros Fund Management’s Portfolio ATXS Stock Details ATXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-873,400	Closed	-$11.4M	–	270
2025 Q4	$11.4M	Buy	+873,400	New	+$10.4M	0.13%	130

Soros Fund Management's ATXS Position: Q1 2026 in Review

Soros Fund Management sold out of Astria Therapeutics (ATXS) in Q1 2026, closing a stake of 873,400 shares — an estimated $11.4M sold.

Soros Fund Management first reported a position in ATXS in Q4 2025 and held it in 1 quarter. The position peaked at $11.4M in Q4 2025. 0 funds tracked by Wall St. Rank hold ATXS as of Q1 2026.

Soros Fund Management reported no remaining Astria Therapeutics position as of Q1 2026 after selling out during the quarter.
Soros Fund Management sold 873,400 Astria Therapeutics shares in Q1 2026, an estimated $11.4M.
Soros Fund Management first reported a position in Astria Therapeutics in Q4 2025 and held it in 1 quarter.
Soros Fund Management's Astria Therapeutics position peaked at $11.4M in Q4 2025.
0 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2026.

Based on Soros Fund Management's 13F filing for Q1 2026, filed 15 May 2026.